曝光台 注意防骗
网曝天猫店富美金盛家居专营店坑蒙拐骗欺诈消费者
include previous hypoglycaemia, long duration of diabetes, and impaired hypoglycaemic awareness.
From the literature review, the risk of hypoglycaemia in Type 1 diabetes is outside that which would be
acceptable in terms of the “1 per cent rule”. States using different risk criteria should make their own
assessment of risk.
For aircrew with Type 2 diabetes, whether taking insulin or not, individuals should be at low risk of
hypoglycaemia. What follows is a cautious protocol that may assist States to determine fitness in
applicants who present with Type 2 diabetes. It provides guidance and may be adjusted by individual
States to suit their own requirements.
PROTOCOL
Initial assessment
ICAO Preliminary Unedited Version — March 2010 III-4A-8
• Stimulated C-peptide levels > 25 per cent of normal;
• No previous hypoglycaemic episodes requiring the intervention of another person;
• Stable blood glucose control: satisfactory HbA1C ~ 7 – 8 per cent;
• Adequate self-monitoring with a memory chip glucose meter;
• No evidence of hypoglycaemic unawareness;
• Good diabetes education and understanding;
• Positive attitude to monitoring and self-care.
An annual assessment may include:
• Review of adequate self-monitoring with a glucose meter;
• Review of blood glucose control with satisfactory, stable HbA1C;
• Report from the treating physician to confirm no complications of diabetes, including renal
and visual complications;
• Annual cardiovascular assessment such as a symptom limited exercise ECG and clinical
review by a cardiologist.
Follow-up should be agreed jointly between the treating physician and the medical assessor.
This approach could be extended to encompass pilots and air traffic control officers with Type 2 diabetes
taking sulphonylureas as well as those requiring insulin.
Acknowledgements
Dr. Hugh O’Neill, Transport Canada
Dr. Warren Silberman, Federal Aviation Administration.
Julie Eden-Brown UK CAA
REFERENCES
Akram K, Pedersen-Bjergaard U, Carstensen B et al. Frequency and risk factors of severe hypoglycaemia
in insulin-treated Type 2 diabetes: a cross-sectional survey. Diabetic Medicine 2006; 23: 750-6.
Barnett A, Grice J. NICE Guidance into Practice. Newer agents in the management of blood glucose in
type 2 diabetes. Practical Diabetes (Supp) 1-11, October 2009.
Berger W. Incidence of severe side-effects during therapy with sulphonylureas and biguanides. Horm
Metab Res 1985; 17:Suppl 14:111-5.
ICAO Preliminary Unedited Version — March 2010 III-4A-9
Berger W, Caduff F, Pasquel M, Rump A. Die relative Haufigkeit der schweren Sulphonylharnstoff -
Hypoglykamie in den letzen 25 Jahren in der Schweiz. Schweiz Med Wochenschr 1986; 116:145-51.
Borch-Johnson K, Kreiner S. Proteinuria: value as predictor of cardiovascular mortality in insulin
dependent diabetes mellitus. Brit Med J 1987; 294:1651-4.
Bott S, Bott U, Berger M et al. Intensified Insulin Therapy and the Risk of Severe Hypoglycaemia.
Diabetologia 1997; 40: 926-32.
Casparie A E, Elving L D. Severe Hypoglycaemia in Diabetic Patients: Frequency, Causes, Prevention.
Diabetes Care 1985; 8: 141-5.
Cox D J, Gonder-Frederick L, Clarke W. Driving decrements in Type 1 diabetes during moderate
hypoglycaemia. Diabetes 1993; 42: 239-43.
Cox D J, Kovatchev B P, Julian D M et al. Frequency of Severe Hypoglycaemia in Insulin Dependent
Diabetes Mellitus can be Predicted from Self-Monitoring Blood Glucose Data. Journal of Clinical
Endocrinology and Metabolism. 1994; 79 (6): 1659-62.
Cox D J, Penberthy J M, Zrebiec J et al. Diabetes and Driving Mishaps. Diabetes Care 2003; 26( 8):
2329 – 34.
Cryer P E. Hypoglycaemia: The limiting factor in the glycaemic management of Type 1 and Type 11
Diabetes. Diabetalogia 2002; 45: 937-48.
Cull CA, Wright AD, Macleod KM et al. Hypoglycaemia in patients with Type 2 diabetes in the
UKPDS. Diabetologia 2001; 44: Suppl 1: A217.
DCCT Research Group. Epidemiology of severe hypoglycaemia in the Diabetes Control and
Complications Trial. Am J Med 1991; 90: 450-9.
Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes
on the development and progression of long term complications in insulin dependent diabetes mellitus. N
Eng J Med 1993; 329:977-86.
DCCT Research Group. Hypoglycaemia in the diabetes control and complications trial. Diabetes 1997;
46: 271-86.
Egger M, Davy-Smith G, Stettler C et al. Risk of Adverse Effects of Intensified Treatment in Insulin
Diabetes Mellitus. Diabetic Medicine 1997; 14: 919-28.
Entmacher P S, Root H F and Marks H H. Longevity of diabetic patients in recent years. Diabetes 1964;
中国航空网 www.aero.cn
航空翻译 www.aviation.cn
本文链接地址：
Manual of Civil Aviation Medicine 1(140)
